Nkarta announces updates to nkx019 and nkx101 clinical development programs

South san francisco, calif., oct. 07, 2021 (globe newswire) -- nkarta, inc. (nasdaq: nktx), a biopharmaceutical company developing engineered natural killer (nk) cell therapies to treat cancer, today announced nkx019 and nkx101 clinical development program updates.
NKTX Ratings Summary
NKTX Quant Ranking